- Home
- SNCR vs STRO Comparison
SNCR vs STRO Comparison
Compare SNCR & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNCR
- STRO
- Stock Information
- Founded
- SNCR 2000
- STRO 2003
- Country
- SNCR United States
- STRO United States
- Employees
- SNCR N/A
- STRO N/A
- Industry
- SNCR EDP Services
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNCR Technology
- STRO Health Care
- Exchange
- SNCR Nasdaq
- STRO Nasdaq
- Market Cap
- SNCR 70.9M
- STRO 69.1M
- IPO Year
- SNCR 2006
- STRO 2018
- Fundamental
- Price
- SNCR $5.37
- STRO $1.06
- Analyst Decision
- SNCR Strong Buy
- STRO Hold
- Analyst Count
- SNCR 1
- STRO 7
- Target Price
- SNCR $13.00
- STRO $1.97
- AVG Volume (30 Days)
- SNCR 72.4K
- STRO 519.9K
- Earning Date
- SNCR 08-11-2025
- STRO 08-07-2025
- Dividend Yield
- SNCR N/A
- STRO N/A
- EPS Growth
- SNCR N/A
- STRO N/A
- EPS
- SNCR N/A
- STRO N/A
- Revenue
- SNCR $171,870,000.00
- STRO $104,473,000.00
- Revenue This Year
- SNCR $1.51
- STRO $65.42
- Revenue Next Year
- SNCR $5.43
- STRO N/A
- P/E Ratio
- SNCR N/A
- STRO N/A
- Revenue Growth
- SNCR 2.54
- STRO N/A
- 52 Week Low
- SNCR $5.25
- STRO $0.52
- 52 Week High
- SNCR $15.46
- STRO $4.80
- Technical
- Relative Strength Index (RSI)
- SNCR 29.45
- STRO 71.61
- Support Level
- SNCR $6.11
- STRO $0.95
- Resistance Level
- SNCR $6.28
- STRO $1.07
- Average True Range (ATR)
- SNCR 0.29
- STRO 0.09
- MACD
- SNCR -0.07
- STRO 0.02
- Stochastic Oscillator
- SNCR 8.63
- STRO 68.42
About SNCR Synchronoss Technologies Inc.
Synchronoss Technologies Inc is a provider of white-label cloud, messaging, digital and network management solutions that enable its customers to keep subscribers, systems, networks and content in sync. The Synchronoss Personal CloudTM solution is designed to create an engaging and trusted customer experience through ongoing content management and engagement. The Synchronoss Personal CloudTM platform is a secure and scalable, white-label platform that allows its customers' subscribers to backup and protect, engage with, and manage their personal content. The company derives revenue from subscriptions and transaction-based fees. A majority of the firm's revenue is generated in the United States, and the rest is from countries across the world.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.